Many cancers evade immune surveillance by suppressing the expression of major histocompatibility class I (MHC-I).38 Loss of MHC-I expression enables tumor cells to escape killing by cytotoxic T lymphocytes.39 Moreover, transcriptional repression of MHC I has been reported to be associated with resistance to cancer immunotherapy.40 In our study, the transcription of MHC I and the interferon-gamma response were repressed in high CNV cancer cells (Fig. 2b). This evidence concerns the gene IFNG and neoplasm.